Abstract 4577
Background
The amplicon of CCND1, FGF3, FGF4, and FGF19 on chromosome 11q13 encodes cyclinD1, regulator of the CDK4/6 cell cycle kinase and FGF ligands for FGFR kinases, which are targets for drug development. We sought to characterize the pan-cancer genomic landscape of this amplicon.
Methods
Tumor samples from 255,117 patients with clinically advanced cancers underwent comprehensive genomic profiling (CGP) with an adaptor-ligation/hybrid capture-based assay of coding DNA of up to 395 cancer-related genes and select introns of 28 genes that are frequently involved in genomic rearrangements to detect base substitutions, insertions and deletions, copy number alterations, and rearrangements.
Results
4% (10,202/255,117) of all cases harbored the 11q13 amplicon (+). The median copy number was 12 (range 6-176). Of the 10 cancers where 11q13+ was most frequent, five were squamous cell carcinomas (SCC) including esophagus SCC (ESCC) (47.3% 11q13+) as the most enriched, head and neck SCC (HNSCC) (17.0%), as well as lung SCC (LSCC) (10.8%). Given ESCC and LSCC are overwhelmingly HPV-, we assessed 11q13 occurrence by HPV status in HNSCC. 3.4% of the 11q13+ HNSCC cases were HPV+, compared to 36.8% of the 11q13- HNSCC samples (p = 9.4e-52). 2 (20%) of the 10 cancers most frequently 11q13+ were the classically ER+ breast invasive lobular carcinoma (17.7%) and breast carcinoma NOS (16.6%). In 441 ER+ breast cancers, 286 (19.8%) were 11q13+. Of these ER+/11q13+ cases, 19.2% also featured ESR1. In contrast, only 14.3% of the ER+/11q13- cases also had ESR1 mutations (p = 0.05). Similarly, in 7103 cases of predominantly castrate resistant prostate cancers, 210 (3.0%) featured 11q13+. 38.6% of the 11q13+ prostate cancer cases also harbored mutations in AR while only 19.9% of the 11q13- cases harbored AR mutations (p = 6.2e-11).
Conclusions
SCCs are enriched for 11q13+ with preliminary evidence for linking them to HPV- status. The co-occurrence of 11q13+ with both ESR1 and AR mutations suggests a co-operative role in acquired resistance to hormonal therapy, but not to TKIs. Further investigation will be 11q13+ in the development of SCC and acquired resistance to hormonal therapies appears warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Foundation Medicine.
Funding
Foundation Medicine.
Disclosure
J.Johnson: Consultant: Foundation Medicine Consultant: Rakuten-Aspyrian. J. Lee: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. R. Madison: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. A.B. Schrock: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. V.A. Miller: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Advisory / Consultancy: Revolution Medicines. B.M. Alexander: Leadership role, Full / Part-time employment: Foundation Medicine; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Schlesinger Associates; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Precision Health Economics; Research grant / Funding (self): Puma; Research grant / Funding (self): Celgene; Research grant / Funding (self): Eli Lilly. J.S. Ross: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche; Officer / Board of Directors: Celsius Therapeutics. J. Chung: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche. S.M. Ali: Shareholder / Stockholder / Stock options, Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / Stock options: Roche; Advisory / Consultancy, Scientific Advisory Board: Incysus Therapeutics; Advisory / Consultancy: Revolution Medicines.
Resources from the same session
4097 - Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option
Presenter: Stephen V Liu
Session: Poster Display session 3
Resources:
Abstract
1129 - Aspirin and Ticagrelor for the prevention of tumour cell induced platelet aggregation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
4514 - Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
Presenter: Michele Maio
Session: Poster Display session 3
Resources:
Abstract
5169 - In vitro functional interrogation of viable Circulating Tumor Associated Cells (C-TACs) for evaluating Platin resistance.
Presenter: Stefan Schuster
Session: Poster Display session 3
Resources:
Abstract
5827 - Targeting ARG2 as a novel therapeutic approach for cancer
Presenter: Marcin Grzybowski
Session: Poster Display session 3
Resources:
Abstract
3129 - MPS1 and PLK1 as new therapy targets in TP53 mutated solid tumors
Presenter: Balazs Gyorffy
Session: Poster Display session 3
Resources:
Abstract
2129 - The Tumor Static Exposure (TSE) concept & utility: application to combination treatment of radiation and radiosensitizing agent in tumor xenograft experiments
Presenter: Samer El Bawab
Session: Poster Display session 3
Resources:
Abstract
1814 - General Methodology to Optimize Tumor Treating Fields Delivery Utilizing Numerical Simulations
Presenter: Noa Urman
Session: Poster Display session 3
Resources:
Abstract
3010 - The Australian Exceptional Responders Program: a National collaboration
Presenter: Megan Barnet
Session: Poster Display session 3
Resources:
Abstract
4489 - A Window of Opportunity Trial of Atorvastatin Targeting p53 Mutant Malignancies
Presenter: Joaquina Baranda
Session: Poster Display session 3
Resources:
Abstract